NASDAQ:JAZZ

Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024

Retrieved on: 
Wednesday, April 24, 2024
Lurbinectedin, BTC, ASCO, BLA, Abstract, Annual general meeting, Jazz Pharmaceuticals, Society, Research, Nightclub

DUBLIN, April 24, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago. Presentations include data from trials of zanidatamab, Zepzelca® (lurbinectedin), and Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn). A poster featuring the study design for the JZP898 Phase 1 trial in progress will also be presented.

Key Points: 
  • DUBLIN, April 24, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago.
  • A poster featuring the study design for the JZP898 Phase 1 trial in progress will also be presented.
  • "We are excited to present data across our oncology pipeline and portfolio at ASCO, particularly the opportunity to provide updated data from the pivotal Phase 2b HERIZON-BTC-01 trial of zanidatamab in HER2-positive BTC presented at last year's meeting.
  • A full list of Jazz or partner-supported presentations at the 2024 ASCO Annual Meeting follows:

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

Retrieved on: 
Wednesday, April 17, 2024
IST, Jazz Pharmaceuticals, Interest

DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets.

Key Points: 
  • DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets.
  • ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update.
  • Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

Retrieved on: 
Wednesday, April 17, 2024
IST, Jazz Pharmaceuticals, Interest

DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets.

Key Points: 
  • DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets.
  • ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update.
  • Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Retrieved on: 
Tuesday, March 12, 2024
GEA, Patient, Breast cancer, Interest, Jazz Pharmaceuticals, Cancer, BTC, Cholangiocarcinoma

DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.

Key Points: 
  • DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.
  • ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers.
  • Interested parties may register for the zanidatamab R&D Day webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Retrieved on: 
Tuesday, March 12, 2024
GEA, Patient, Breast cancer, Interest, Jazz Pharmaceuticals, Cancer, BTC, Cholangiocarcinoma

DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.

Key Points: 
  • DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.
  • ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers.
  • Interested parties may register for the zanidatamab R&D Day webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors

Retrieved on: 
Tuesday, February 27, 2024
CFO, ICON, ICON PLC, Biotechnology, Jazz Pharmaceuticals, Bank, Female, Growth, Greencore, Audit committee, Organization, Patient, McKinsey & Company, Chair, ASOS, KPMG, UDG Healthcare, Nightclub

DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors. Mr. Kennedy, Chair and Governor of the Bank of Ireland, has been appointed to the Jazz Board and will serve on the Audit Committee effective March 1, 2024. Peter Gray has decided not to seek re-election to the Jazz Board at the next Annual General Meeting, expected in July 2024.

Key Points: 
  • DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors.
  • Mr. Kennedy, Chair and Governor of the Bank of Ireland, has been appointed to the Jazz Board and will serve on the Audit Committee effective March 1, 2024.
  • "We are thrilled to welcome Patrick to the Board," said Bruce Cozadd, chairman and CEO, Jazz Pharmaceuticals.
  • Mr. Kennedy brings over 30 years of experience to the Jazz Board with a successful track record across a range of global businesses.

Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors

Retrieved on: 
Tuesday, February 27, 2024
CFO, ICON, ICON PLC, Biotechnology, Jazz Pharmaceuticals, Bank, Female, Growth, Greencore, Audit committee, Organization, Patient, McKinsey & Company, Chair, ASOS, KPMG, UDG Healthcare, Nightclub

DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors. Mr. Kennedy, Chair and Governor of the Bank of Ireland, has been appointed to the Jazz Board and will serve on the Audit Committee effective March 1, 2024. Peter Gray has decided not to seek re-election to the Jazz Board at the next Annual General Meeting, expected in July 2024.

Key Points: 
  • DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors.
  • Mr. Kennedy, Chair and Governor of the Bank of Ireland, has been appointed to the Jazz Board and will serve on the Audit Committee effective March 1, 2024.
  • "We are thrilled to welcome Patrick to the Board," said Bruce Cozadd, chairman and CEO, Jazz Pharmaceuticals.
  • Mr. Kennedy brings over 30 years of experience to the Jazz Board with a successful track record across a range of global businesses.

Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer

Retrieved on: 
Wednesday, February 21, 2024
Jazz Pharmaceuticals, Risk management, Growth, Information services, Accounting, Patient, Treasury

DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024. Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023. 

Key Points: 
  • DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024.
  • Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023.
  • Mr. Johnson joins Jazz Pharmaceuticals with over 35 years of financial experience, most recently leading Eli Lilly and Company's treasury and investor relations operations as Group Vice President of Finance.
  • In his new role, Mr. Johnson will oversee financial reporting, accounting, tax, treasury, risk management, financial planning and analysis, information services and facilities.

Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer

Retrieved on: 
Wednesday, February 21, 2024
Jazz Pharmaceuticals, Risk management, Growth, Information services, Accounting, Patient, Treasury

DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024. Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023. 

Key Points: 
  • DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024.
  • Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023.
  • Mr. Johnson joins Jazz Pharmaceuticals with over 35 years of financial experience, most recently leading Eli Lilly and Company's treasury and investor relations operations as Group Vice President of Finance.
  • In his new role, Mr. Johnson will oversee financial reporting, accounting, tax, treasury, risk management, financial planning and analysis, information services and facilities.

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

Retrieved on: 
Tuesday, February 20, 2024
Jazz Pharmaceuticals, Conference

DUBLIN, Feb. 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:

Key Points: 
  • DUBLIN, Feb. 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:
    TD Cowen's 44th Annual Health Care Conference on Monday, March 4, 2024
    Fireside chat at 7:30 a.m. PT / 10:30 a.m.
  • ET / 3:30 p.m. GMT
    Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024
    Fireside chat at 11:00 a.m. PT / 2:00 p.m.
  • ET / 7:00 p.m. GMT
    Audio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • A replay of the webcasts will be archived on the website for 30 days.